287 related articles for article (PubMed ID: 31795143)
41. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
Feng H; Jenkins LM; Durell SR; Hayashi R; Mazur SJ; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Bai Y
Structure; 2009 Feb; 17(2):202-10. PubMed ID: 19217391
[TBL] [Abstract][Full Text] [Related]
42. Investigation of the MDM2-binding potential of de novo designed peptides using enhanced sampling simulations.
Durojaye OA; Yekeen AA; Idris MO; Okoro NO; Odiba AS; Nwanguma BC
Int J Biol Macromol; 2024 Jun; 269(Pt 2):131840. PubMed ID: 38679255
[TBL] [Abstract][Full Text] [Related]
43. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
44. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
Niu RJ; Zheng QC; Zhang JL; Zhang HX
J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
[TBL] [Abstract][Full Text] [Related]
45. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
[TBL] [Abstract][Full Text] [Related]
46. Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells.
Alshatwi AA; Han CT; Schoene NW; Lei KY
Exp Biol Med (Maywood); 2006 May; 231(5):611-8. PubMed ID: 16636310
[TBL] [Abstract][Full Text] [Related]
47. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
[TBL] [Abstract][Full Text] [Related]
48. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.
Joseph TL; Lane D; Verma CS
Cell Cycle; 2010 Nov; 9(22):4560-8. PubMed ID: 21088491
[TBL] [Abstract][Full Text] [Related]
49. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
50. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
[No Abstract] [Full Text] [Related]
51. Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Guerlavais V; Sawyer TK; Carvajal L; Chang YS; Graves B; Ren JG; Sutton D; Olson KA; Packman K; Darlak K; Elkin C; Feyfant E; Kesavan K; Gangurde P; Vassilev LT; Nash HM; Vukovic V; Aivado M; Annis DA
J Med Chem; 2023 Jul; 66(14):9401-9417. PubMed ID: 37439511
[TBL] [Abstract][Full Text] [Related]
52. Binding Ensembles of
Lang L; Perez A
Molecules; 2021 Jan; 26(1):. PubMed ID: 33401765
[TBL] [Abstract][Full Text] [Related]
53. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2.
Teufel DP; Bycroft M; Fersht AR
Oncogene; 2009 May; 28(20):2112-8. PubMed ID: 19363523
[TBL] [Abstract][Full Text] [Related]
54. P53 mdm2 inhibitors.
Khoury K; Dömling A
Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
[TBL] [Abstract][Full Text] [Related]
55. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
56. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
57. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53.
Zhu Q; Wani G; Wani MA; Wani AA
Cancer Res; 2001 Jan; 61(1):64-70. PubMed ID: 11196199
[TBL] [Abstract][Full Text] [Related]
58. SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription.
Pavithra L; Mukherjee S; Sreenath K; Kar S; Sakaguchi K; Roy S; Chattopadhyay S
J Mol Biol; 2009 May; 388(4):691-702. PubMed ID: 19303885
[TBL] [Abstract][Full Text] [Related]
59. Toward Understanding the Molecular Recognition of Albumin by p53-Activating Stapled Peptide ATSP-7041.
Tiwari G; Verma CS
J Phys Chem B; 2017 Feb; 121(4):657-670. PubMed ID: 28048940
[TBL] [Abstract][Full Text] [Related]
60. Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains.
Polley S; Guha S; Roy NS; Kar S; Sakaguchi K; Chuman Y; Swaminathan V; Kundu T; Roy S
J Mol Biol; 2008 Feb; 376(1):8-12. PubMed ID: 18155245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
